# GAGE2A

## Overview
GAGE2A is a gene that encodes the G antigen 2A protein, which is a member of the cancer-testis antigen family. These antigens are typically expressed in a restricted manner, predominantly in the testis and various cancerous tissues, making them of particular interest in cancer research and immunotherapy (Gjerstorff2012GAGE). The G antigen 2A protein is involved in cellular processes related to cancer progression, potentially through its role in chromatin organization and interactions with other proteins within the cell (Gjerstorff2012GAGE). As a hub gene in protein-protein interaction networks, particularly in the context of TP53 mutations in hepatocellular carcinoma, GAGE2A is implicated in complex cellular pathways that may influence tumor development and metastasis (Yang2022Identification). Its expression is associated with poor prognosis in several cancers, including ovarian and liver cancer, suggesting its potential as a prognostic marker and a target for therapeutic interventions (Zhong2020A; Vlasenkova2023Characterization).

## Clinical Significance
GAGE2A is implicated in several cancers due to its altered expression levels. In ovarian cancer, GAGE2A is significantly up-regulated in tumor tissues compared to healthy ovarian tissues. It acts as a hub gene in tumor samples, and its increased expression is associated with reduced disease-free survival, indicating a poorer prognosis for patients. This suggests that GAGE2A could serve as a prognostic marker for ovarian cancer (Vlasenkova2023Characterization).

In liver cancer, GAGE2A is part of a five-gene signature that predicts prognosis. It is positively related to lymphatic metastasis, highlighting its potential role as a prognostic marker in this cancer type (Zhong2020A).

GAGE2A is also expressed in gastroesophageal adenocarcinoma (GEAC), where its expression, particularly in combination with other GAGE genes, is associated with worse overall survival in patients not treated with immune checkpoint inhibitors (Kalvapudi2024Cancertestis).

In chronic myeloid leukemia (CML), GAGE2A, referred to as GAGE-2, is part of a group of cancer/testis antigens that are expressed in a subset of patients, potentially contributing to disease progression by providing malignant stem cells with an evolutionary advantage (MendozaSalas2016Frequency).

## Interactions
GAGE2A, a member of the GAGE family of proteins, is known to be part of the cancer-testis antigen family and is implicated in various interactions within the cell. While specific physical interactions of GAGE2A with other proteins or nucleic acids are not detailed in the available context, it is mentioned as a hub gene in a protein-protein interaction network analysis related to TP53 mutations in hepatocellular carcinoma (HCC) (Yang2022Identification). This suggests that GAGE2A may play a role in complex cellular pathways associated with cancer progression.

The GAGE family, in general, is characterized by its ability to bind double-stranded DNA in a sequence-independent manner, similar to High Mobility Group (HMG) domain proteins, which may imply a potential for GAGE2A to engage in similar interactions (Gjerstorff2012GAGE). However, specific interactions involving GAGE2A itself are not explicitly detailed in the provided context. The role of GAGE proteins in chromatin organization and their recruitment to the nuclear envelope by Germ Cell-less (GCL) proteins further suggests a potential involvement in nuclear processes, although direct evidence for GAGE2A is not provided (Gjerstorff2012GAGE).


## References


[1. (MendozaSalas2016Frequency) I. Mendoza-Salas, I. Olarte-Carrillo, E. Miranda-Peralta, C. Ramos-Peñafiel, A. García-Laguna, R. Cerón-Maldonado, A. De la Cruz-Rosas, J. Collazo-Jaloma, J. Kassac-Ipiña, E. Mendoza-García, E. Ramón-Gallegos, and A. Martínez-Tovar. Frequency of cancer testis antigens in chronic myeloid leukemia. Revista Médica del Hospital General de México, 79(2):46–54, April 2016. URL: http://dx.doi.org/10.1016/j.hgmx.2015.10.003, doi:10.1016/j.hgmx.2015.10.003. This article has 0 citations.](https://doi.org/10.1016/j.hgmx.2015.10.003)

2. (Zhong2020A) A novel five-gene signature for predicting prognosis in liver cancer. This article has 1 citations.

[3. (Yang2022Identification) Yang Yang, Yajuan Qu, Zhaopeng Li, Zhiyong Tan, Youming Lei, and Song Bai. Identification of novel characteristics in tp53-mutant hepatocellular carcinoma using bioinformatics. Frontiers in Genetics, May 2022. URL: http://dx.doi.org/10.3389/fgene.2022.874805, doi:10.3389/fgene.2022.874805. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2022.874805)

[4. (Gjerstorff2012GAGE) Morten F. Gjerstorff, Heike I. Rösner, Christina B. Pedersen, Katrine B. V. Greve, Steffen Schmidt, Katherine L. Wilson, Jan Mollenhauer, Hüseyin Besir, Flemming M. Poulsen, Niels Erik Møllegaard, and Henrik J. Ditzel. Gage cancer-germline antigens are recruited to the nuclear envelope by germ cell-less (gcl). PLoS ONE, 7(9):e45819, September 2012. URL: http://dx.doi.org/10.1371/journal.pone.0045819, doi:10.1371/journal.pone.0045819. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0045819)

[5. (Kalvapudi2024Cancertestis) Sukumar Kalvapudi, Akhil Goud Pachimatla, R. J. Seager, Jeffrey Conroy, Sarabjot Pabla, and Sarbajit Mukherjee. Cancer/testis antigen expression and co-expression patterns in gastroesophageal adenocarcinoma. Medical Oncology, August 2024. URL: http://dx.doi.org/10.1007/s12032-024-02475-6, doi:10.1007/s12032-024-02475-6. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12032-024-02475-6)

[6. (Vlasenkova2023Characterization) Ramilia Vlasenkova, Daliya Konysheva, Alsina Nurgalieva, and Ramziya Kiyamova. Characterization of cancer/testis antigens as prognostic markers of ovarian cancer. Diagnostics, 13(19):3092, September 2023. URL: http://dx.doi.org/10.3390/diagnostics13193092, doi:10.3390/diagnostics13193092. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/diagnostics13193092)